These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 7824275

  • 1. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X, Dougall WC, Fei Z, Greene MI.
    Oncogene; 1995 Jan 05; 10(1):211-9. PubMed ID: 7824275
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X, O'Rourke DM, Zhao H, Greene MI.
    Oncogene; 1996 Nov 21; 13(10):2149-57. PubMed ID: 8950982
    [Abstract] [Full Text] [Related]

  • 3. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 21; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
    Juang SH, Carvajal ME, Whitney M, Liu Y, Carraway CA.
    Oncogene; 1996 Mar 07; 12(5):1033-42. PubMed ID: 8649794
    [Abstract] [Full Text] [Related]

  • 5. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF.
    Oncogene; 1997 Feb 13; 14(6):687-96. PubMed ID: 9038376
    [Abstract] [Full Text] [Related]

  • 6. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 7. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ, Maihle NJ.
    Exp Cell Res; 2002 Apr 15; 275(1):9-16. PubMed ID: 11925101
    [Abstract] [Full Text] [Related]

  • 8. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
    Cao H, Decker S, Stern DF.
    Oncogene; 1991 May 15; 6(5):705-11. PubMed ID: 1675782
    [Abstract] [Full Text] [Related]

  • 9. The role of the neu oncogene product in cell transformation and normal development.
    Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI.
    Princess Takamatsu Symp; 1988 May 15; 19():45-57. PubMed ID: 2908355
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
    Petti LM, Irusta PM, DiMaio D.
    Oncogene; 1998 Feb 19; 16(7):843-51. PubMed ID: 9484775
    [Abstract] [Full Text] [Related]

  • 11. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
    Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI.
    Oncogene; 1994 Aug 19; 9(8):2109-23. PubMed ID: 7913542
    [Abstract] [Full Text] [Related]

  • 12. Neu and its ligands: from an oncogene to neural factors.
    Peles E, Yarden Y.
    Bioessays; 1993 Dec 19; 15(12):815-24. PubMed ID: 7908191
    [Abstract] [Full Text] [Related]

  • 13. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K.
    Clin Cancer Res; 2008 Jul 15; 14(14):4437-45. PubMed ID: 18628457
    [Abstract] [Full Text] [Related]

  • 14. Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway.
    Li K, Shao R, Hung MC.
    Oncogene; 1999 Apr 22; 18(16):2617-26. PubMed ID: 10353605
    [Abstract] [Full Text] [Related]

  • 15. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.
    Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE.
    Gastroenterology; 2005 Dec 22; 129(6):2047-57. PubMed ID: 16344070
    [Abstract] [Full Text] [Related]

  • 16. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
    Qian X, Dougall WC, Hellman ME, Greene MI.
    Oncogene; 1994 May 22; 9(5):1507-14. PubMed ID: 7908733
    [Abstract] [Full Text] [Related]

  • 17. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
    Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C, Esselman WJ, Welsch CW.
    Cancer Res; 1993 May 15; 53(10 Suppl):2272-8. PubMed ID: 8097963
    [Abstract] [Full Text] [Related]

  • 18. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.
    Kumagai T, Davis JG, Horie T, O'Rourke DM, Greene MI.
    Proc Natl Acad Sci U S A; 2001 May 08; 98(10):5526-31. PubMed ID: 11320205
    [Abstract] [Full Text] [Related]

  • 19. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
    Kang KS, Sun W, Nomata K, Morita I, Cruz A, Liu CJ, Trosko JE, Chang CC.
    Mol Carcinog; 1998 Apr 08; 21(4):225-33. PubMed ID: 9585252
    [Abstract] [Full Text] [Related]

  • 20. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes.
    Qian X, O'Rourke DM, Fei Z, Zhang HT, Kao CC, Greene MI.
    J Biol Chem; 1999 Jan 08; 274(2):574-83. PubMed ID: 9872991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.